Success Stories: EB-1A Approved with NAILG’s Assistance of a PhD Candidate in Biostatistics
On April 3rd, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a PhD Candidate in the Field of Biostatistics (Approval Notice).
General Field: Biostatistics
Position at the Time of Case Filing: PhD Candidate
Country of Origin: China
State of Residence at the Time of Filing: New York
Approval Notice Date: April 3rd, 2025
Processing Time: 1 year, 2 months, 13 days
Case Summary:
The North America Immigration Law Group (NAILG) is pleased to share the EB-1A approval of a distinguished researcher whose work sits at the intersection of biostatistics, public health, and healthcare innovation. Our client has built a reputation for addressing complex medical and societal challenges, including healthcare disparities, infectious disease treatment, and the advancement of predictive health models.
Throughout her career, she has developed novel statistical methodologies and applied them to real-world healthcare issues. Her research has contributed significantly to areas such as telemedicine, antibiotic stewardship, infectious disease modeling, and cardiovascular disease prediction. These contributions not only advance scientific understanding but also inform clinical practices and global public health policies.
Her expertise is well-documented:
- She has authored 15 peer-reviewed journal articles (including 2 as first author) and contributed to 1 conference abstract.
- Her work has been cited 771 times, reflecting the broad applicability and influence of her research.
- She has been entrusted to conduct at least 27 peer reviews for respected journals, a recognition of her authority and leadership in the field.
- Her projects were funded by leading institutions, including the National Science Foundation, Pfizer, the National Institutes of Mental Health, and the National Institutes of Health. These partnerships underscore the value of her work in driving forward both academic inquiry and practical health interventions.
"It is not difficult to see the benefits that come from a researcher as astute as [client]. Her work has implications for both the detailed application of health practices as well as the broader implementation schemes of public health, both informed by statistical analysis undertaken by [client]. In terms of the former, [client]'s work allows clinicians a better understanding of how their treatment methods work on patients, with an understanding that, for example, bedaquiline is more effective than delamind. This is important on an individual level, as it allows practitioners to prescribe a more effective drug. However, her work is not limited to the individual, as it then has significant implications for a broader picture. The World Health Organization, for instance, has implemented guidelines on the usage of bedaquiline, classifying it as a 'Class A priority drug' for tuberculosis patients. Global public health policy is therefore informed by [client]'s work, offering a universally-applicable finding."
Our legal team at NAILG prepared a petition that emphasized how our client’s work has not only achieved academic distinction but also translated into meaningful, real-world outcomes. Her efforts are helping to shape a healthier, more equitable future—both in the United States and globally.
We are honored to have supported her through this important milestone and look forward to the continued impact of her research.